Carpenter R N, Brown I, Mitchell J S
Int J Radiat Oncol Biol Phys. 1983 Jan;9(1):51-5. doi: 10.1016/0360-3016(83)90208-0.
Uptake studies of the potential endoradiotherapeutic agent, 6-125I-iodo-2-methyl-1,4-naphthoquinol bis(diammonium phosphate) have been carried out in vitro on a wide range of normal and malignant human cells. In general, for a standardized dose of 0.1 microCi/ml, the uptake of the compound into normal cells was 0.0015-0.135 pCi/cell. Uptake into malignant cells was significantly higher than normal cells; uptakes of 0.89-11.3 pCi/cell were noted for melanoma, teratoma of testis, osteosarcoma and adenocarcinoma of colon and pancreas. Comparative uptake ratios for melanoma: Chang liver cells and testicular teratoma:normal testis were 29 23, respectively. Larger uptake ratios are usually observed with higher doses.
对潜在的内放射治疗剂6-¹²⁵I-碘-2-甲基-1,4-萘醌双(磷酸二铵)进行了体外摄取研究,研究对象为多种正常和恶性人类细胞。一般来说,对于0.1微居里/毫升的标准化剂量,该化合物在正常细胞中的摄取量为0.0015-0.135皮居里/细胞。在恶性细胞中的摄取量明显高于正常细胞;黑色素瘤、睾丸畸胎瘤、骨肉瘤以及结肠和胰腺腺癌的摄取量为0.89-11.3皮居里/细胞。黑色素瘤与张氏肝细胞、睾丸畸胎瘤与正常睾丸的摄取比分别为29和23。通常剂量越高,摄取比越大。